MEDITE Cancer Reorganizes Operations in Germany

MEDITE Cancer Diagnostics (OTCQB:MDIT) announced some restructuring plans for its German organization.

As quoted in the press release:

Effective immediately, three new reporting lines have been established for the organization in Germany. All sales, marketing and sales fulfillment personnel and activities will report into Jeff Rencher, Chief Marketing and Business Development Officer. All manufacturing, R&D, technical service and quality management personnel and activities will report into Stephen Von Rump, Chief Commercialization and Strategy Officer. All financial personnel and activities will report into Susan Weisman, Chief Financial Officer. Mr. Rencher, Mr. Von Rump and Ms. Weisman all report directly to David Patterson, Chief Executive Officer of the Company.

“The purpose of this reorganization is to position the Company for the next level of growth and profitability,” said Mr. Patterson. “To reach our goals of globalization and revenue increase requires a different approach to the business. We needed to integrate the organization and put in place the infrastructure needed to achieve those goals.”

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.

Biotech

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply